India’s Glenmark Confirms Abbott Sued It Over Tarka Generic (India)
This article was originally published in PharmAsia News
Executive Summary
India's Glenmark Pharmaceuticals confirms Abbott Laboratories has sued it in the United States to block its FDA application for a generic version of Tarka (trandolapril, verapamil hydrochloride) for treating hypertension. Glenmark believes it was the first to file for a generic, the first for the company, but Abbott said the application violates its patent. Tarka has generated $100 million in U.S. sales for Abbott. (Click here for more ) "Glenmark Confirms Abbott Suit Against Tarka Generic" Economic Times (India) (12/13/07)
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.